Paradoxical growth of Candida in vitro at echinocandin concentrations exceeding the MIC is well described, but the clinical relevance is unknown. We assessed echinocandin paradoxical effects against Candida bloodstream isolates (BSI) in the presence or absence of human serum and investigated regulatory mechanisms. As determined by broth microdilution, a paradoxical effect was evident for 60% (18/30), 23% (7/30), and 13% (4/30) of Candida albicans BSI exposed to caspofungin, anidulafungin, and micafungin, respectively, at achievable human serum concentrations (<8 g/ml). A paradoxical effect was not evident among 34 C. glabrata BSI and was observed only for caspofungin against C. parapsilosis (4%, 1/23). As determined in time-kill studies, a caspofungin paradoxical effect was demonstrated by C. albicans (2/3), C. glabrata (1/3), and C. parapsilosis (1/3), including BSI that were determined to be negative by microdilution. In 50% human serum, a paradoxical effect was eliminated at caspofungin concentrations up to 64 g/ml for 100% (8/8) of the C. albicans BSI. A caspofungin paradoxical effect was also eliminated by chitin synthase inhibitor nikkomycin Z and at achievable concentrations of calcineurin pathway inhibitors, tacrolimus and cyclosporine. Moreover, these agents were synergistic with caspofungin against 100, 100, and 88% (7/8) of C. albicans, respectively, and exerted their own paradoxical effects. Finally, paradoxical growth was eliminated in C. albicans irs4-and inp51-null mutants, which lack phosphatidylinositol-(4,5)-bisphosphate 5 -phosphatase. Our findings suggest that the paradoxical effect is unlikely to be important in vivo but remains an important tool to study cell wall stress responses. We implicate the Irs4-Inp51 phosphatidylinositol-(4,5)-bisphosphate 5 -phosphatase as a novel regulator of paradoxical growth.The echinocandins have emerged as frontline agents for the treatment of invasive candidiasis (20). These agents exert concentration-dependent fungicidal effects through noncompetitive inhibition of -1-3-glucan synthase, an enzyme that produces a major constituent of the fungal cell wall. Echinocandins are well tolerated in humans at up to three times the standard doses (4), a circumstance that has created interest in exploring the use of high-dose regimens to maximize clinical efficacy. Along these lines, concerns have been expressed about the possible therapeutic implications of an in vitro paradoxical effect, in which certain Candida isolates exhibit increased growth in the presence of echinocandin concentrations above the minimum inhibitory concentration (MIC). Although the paradoxical effect is typically apparent in vitro at concentrations that are achievable in human serum with conventional dosing strategies, the clinical relevance of the phenomenon in the treatment of patients with candidiasis is unproven.To date, paradoxical effects have been demonstrated against Candida albicans, C. parapsilosis, C. krusei, C. tropicalis, and C. dubliniensis isolates (3,5,10,16,23,25,28). Moreover...